Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. Simcere Pharmaceutical Group Limited
  6. Summary
    2096   HK0000658531

SIMCERE PHARMACEUTICAL GROUP LIMITED

(2096)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Hong Kong Stock Exchange
01/12/2022 01/13/2022 01/14/2022 01/17/2022 01/18/2022 Date
9.26 9.11 9.68 11.02 10.8 Last
2358000 897000 6570000 26859200 13267070 Volume
-1.07% -1.62% +6.26% +13.84% -2.00% Change
Estimated financial data (e) (USD)
Sales 2021 805 M - -
Net income 2021 144 M - -
Net Debt 2021 232 M - -
P/E ratio 2021 28,1x
Yield 2021 -
Sales 2022 1 027 M - -
Net income 2022 138 M - -
Net Debt 2022 117 M - -
P/E ratio 2022 25,2x
Yield 2022 -
Capitalization 3 659 M 3 659 M -
EV / Sales 2021 4,83x
EV / Sales 2022 3,68x
Nbr of Employees 6 204
Free-Float 18,5%
More Financials
Company
Simcere Pharmaceutical Group Ltd is a company engaged in research and development, production and sales of drugs. The Company's main products are generic drugs, including Bicun used for central nervous system diseases, Jepaso and Jiebaili used for oncology, as well as Yingtaiqing used for autoimmune diseases. The Company also produces innovative drugs, such as Endostar used for oncology. The Company is also involved... 
Sector
Pharmaceuticals
Calendar
-
More about the company
Ratings of Simcere Pharmaceutical Group Limited
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about SIMCERE PHARMACEUTICAL GROUP LIMITED
2021Simcere Pharmaceutical to Grant Restricted ShareUnits under Restricted Share Unit Schem..
MT
2021Simcere Pharmaceutical Group Limited Enters into the Xianbo Property Lease and Comprehe..
CI
2021Center for Drug Evaluation of the National Medical Products Administration of China Inc..
CI
2021Simcere Pharma Strikes Licensing Deal for China Rights to Nervous System Disease Drug
MT
2021Simcere Pharma Wins OK to Start Clinical Trials in China for Two Cancer Drugs
MT
2021Simcere Pharmaceutical Group Limited Announces Clinical Trial Approval for SIM0235 Issu..
CI
2021China Accepts Simcere Pharma's Marketing Application for Lung Cancer Drug; Shares Jump ..
MT
2021Simcere Pharma's Solid Tumor Drug Gets Marketing Approval in China
MT
2021Simcere Pharmaceutical Group Limited Announces Conditional Approval on the Marketing of..
CI
2021Simcere and Shanghai Institute of Materia Medica Enter Collaboration to Jointly Develop..
CI
2021Simcere Pharmaceutical Says Unaware of Reasons for 'Unusual' Price, Trading Volume Move..
MT
2021Simcere Pharmaceutical Allots Nearly 9 Million Shares Under Restricted Share Unit Schem..
MT
2021Certain Ordinary Shares of Simcere Pharmaceutical Group Limited are subject to a Lock-U..
CI
2021SIMCERE PHARMACEUTICAL : H1 Profit Surges 200% on 'Rapid' Revenue Growth From Stroke Treat..
MT
2021Simcere Pharmaceutical Group Limited Announces Unaudited Consolidated Financial Results..
CI
More news
News in other languages on SIMCERE PHARMACEUTICAL GROUP LIMITED
2021Simcere Pharmaceutical Group Limited conclut avec Shanghai Xianbo un accord-cadre porta..
2021Le Centre d'évaluation des médicaments de l'Administration nationale des produits médic..
2021Simcere Pharma conclut un accord de licence pour les droits chinois d'un médicament con..
2021Simcere Pharma obtient l'autorisation de lancer des essais cliniques en Chine pour deux..
2021La Chine accepte la demande de commercialisation de Simcere Pharma pour un médicament c..
More news
Analyst Recommendations on SIMCERE PHARMACEUTICAL GROUP LIMITED
More recommendations
Chart SIMCERE PHARMACEUTICAL GROUP LIMITED
Duration : Period :
Simcere Pharmaceutical Group Limited Technical Analysis Chart | 2096 | HK0000658531 | MarketScreener
Technical analysis trends SIMCERE PHARMACEUTICAL GROUP LIMITED
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 8,80 CNY
Average target price 10,31 CNY
Spread / Average Target 17,1%
EPS Revisions
Managers and Directors
Jin Sheng Ren President
Yu Shan Wan Chief Financial Officer & Executive Director
Pin Wang Chief Scientific Officer
Rui Lin Song Independent Non-Executive Directors
Jian Guo Wang Independent Non-Executive Director